Tobias Feldreich1,2, Axel C Carlsson2,3, Johanna Helmersson-Karlqvist4, Ulf Risérus5, Anders Larsson4, Lars Lind3, Johan Ärnlöv1,2. 1. School of Health and Social Studies, Dalarna University, Falun, Sweden. 2. Division of Family Medicine and Primary Care, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden. 3. Cardiovascular Epidemiology, Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden. 4. Clinical Chemistry, Uppsala University Hospital, Uppsala, Sweden. 5. Department of Public Health and Caring Sciences, Uppsala University Hospital, Uppsala, Sweden.
Abstract
BACKGROUND AND OBJECTIVES: The matricellular protein osteopontin is involved in the pathogenesis of both kidney and cardiovascular disease. However, whether circulating and urinary osteopontin levels are associated with the risk of these diseases is less studied. DESIGN SETTING PARTICIPANTS AND MEASUREMENTS: A community-based cohort of elderly men (Uppsala Longitudinal Study of Adult Men [ULSAM]; n = 741; mean age: 77 years) was used to study the associations between plasma and urinary osteopontin, incident chronic kidney disease, and the risk of cardiovascular death during a median of 8 years of follow-up. RESULTS: There was no significant cross-sectional correlation between plasma and urinary osteopontin (Spearman ρ = 0.07, p = 0.13). Higher urinary osteopontin, but not plasma osteopontin, was associated with incident chronic kidney disease in multivariable models adjusted for age, cardiovascular risk factors, baseline glomerular filtration rate, urinary albumin/creatinine ratio, and the inflammatory markers interleukin 6 and high-sensitivity C-reactive protein (odds ratio for 1 standard deviation [SD] of urinary osteopontin, 1.42, 95% CI 1.00-2.02, p = 0.048). Conversely, plasma osteopontin, but not urinary osteopontin, was independently associated with cardiovascular death (multivariable hazard ratio per SD increase, 1.35, 95% CI 1.14-1.58, p < 0.001, and 1.00, 95% CI 0.79-1.26, p = 0.99, respectively). The addition of plasma osteopontin to a model with established cardiovascular risk factors significantly increased the C-statistics for the prediction of cardiovascular death (p < 0.002). CONCLUSIONS: Higher urinary osteopontin specifically predicts incident chronic kidney disease, while plasma osteopontin specifically predicts cardiovascular death. Our data put forward osteopontin as an important factor in the detrimental interplay between the kidney and the cardiovascular system. The clinical implications, and why plasma and urinary osteopontin mirror different pathologies, remain to be established.
BACKGROUND AND OBJECTIVES: The matricellular protein osteopontin is involved in the pathogenesis of both kidney and cardiovascular disease. However, whether circulating and urinary osteopontin levels are associated with the risk of these diseases is less studied. DESIGN SETTING PARTICIPANTS AND MEASUREMENTS: A community-based cohort of elderly men (Uppsala Longitudinal Study of Adult Men [ULSAM]; n = 741; mean age: 77 years) was used to study the associations between plasma and urinary osteopontin, incident chronic kidney disease, and the risk of cardiovascular death during a median of 8 years of follow-up. RESULTS: There was no significant cross-sectional correlation between plasma and urinary osteopontin (Spearman ρ = 0.07, p = 0.13). Higher urinary osteopontin, but not plasma osteopontin, was associated with incident chronic kidney disease in multivariable models adjusted for age, cardiovascular risk factors, baseline glomerular filtration rate, urinary albumin/creatinine ratio, and the inflammatory markers interleukin 6 and high-sensitivity C-reactive protein (odds ratio for 1 standard deviation [SD] of urinary osteopontin, 1.42, 95% CI 1.00-2.02, p = 0.048). Conversely, plasma osteopontin, but not urinary osteopontin, was independently associated with cardiovascular death (multivariable hazard ratio per SD increase, 1.35, 95% CI 1.14-1.58, p < 0.001, and 1.00, 95% CI 0.79-1.26, p = 0.99, respectively). The addition of plasma osteopontin to a model with established cardiovascular risk factors significantly increased the C-statistics for the prediction of cardiovascular death (p < 0.002). CONCLUSIONS: Higher urinary osteopontin specifically predicts incident chronic kidney disease, while plasma osteopontin specifically predicts cardiovascular death. Our data put forward osteopontin as an important factor in the detrimental interplay between the kidney and the cardiovascular system. The clinical implications, and why plasma and urinary osteopontin mirror different pathologies, remain to be established.
Authors: Johan Lorenzen; Robert Krämer; Volker Kliem; Stefanie M Bode-Boeger; Hendrik Veldink; Hermann Haller; Danilo Fliser; Jan T Kielstein Journal: Eur J Clin Invest Date: 2010-04 Impact factor: 4.686
Authors: Johan M Lorenzen; Carsten Hafer; Robert Faulhaber-Walter; Philipp Kümpers; Jan T Kielstein; Hermann Haller; Danilo Fliser Journal: Nephrol Dial Transplant Date: 2010-08-23 Impact factor: 5.992
Authors: Kyo Won Seo; Seung Jin Lee; Byeong Hyeok Ye; Young Whan Kim; Sun Sik Bae; Chi Dae Kim Journal: J Mol Cell Cardiol Date: 2015-05-15 Impact factor: 5.000
Authors: Florian W Kiefer; Maximilian Zeyda; Karina Gollinger; Birgit Pfau; Angelika Neuhofer; Thomas Weichhart; Marcus D Säemann; René Geyeregger; Michaela Schlederer; Lukas Kenner; Thomas M Stulnig Journal: Diabetes Date: 2010-01-27 Impact factor: 9.461
Authors: Hermine I Brunner; Gaurav Gulati; Marisa S Klein-Gitelman; Kelly A Rouster-Stevens; Lori Tucker; Stacey P Ardoin; Karen B Onel; Rylie Mainville; Jessica Turnier; Pinar Ozge Avar Aydin; David Witte; Bin Huang; Michael R Bennett; Prasad Devarajan Journal: Pediatr Nephrol Date: 2018-08-29 Impact factor: 3.714